Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

AstraZeneca will keep UK investment freeze if no Brexit clarity

share with twitter share with LinkedIn share with facebook
10/15/2018 | 01:04pm EDT
FILE PHOTO: A sign is seen at an AstraZeneca site in Macclesfield

PARIS (Reuters) - AstraZeneca will keep its freeze on manufacturing investments in Britain if the country's exit from the European Union fails to give enough clarity on future trading relations, the drugmaker's chairman was quoted as saying on Monday.

The comments add to pressure on British Prime Minister Theresa May to rethink her plan for leaving the EU after Brexit talks reached a stand-off at the weekend over arrangements for the UK border with Ireland.

"If a transition deal does not make clear what will happen in the future, we will maintain our decision not to invest," Leif Johansson told France's Le Monde newspaper.

"A Brexit agreement will need to ensure that Britain does not become an isolated island in the middle of the Atlantic Ocean," he added.

A spokesman for AstraZeneca said Johansson was referring to a freeze on investments in manufacturing announced in 2017.

"There has been no change to our investment plans in the UK," the spokesman said.

AstraZenca has already spent 40 million pounds ($53 million) stockpiling medicines in Britain and continental Europe to prevent supply disruptions if the two sides fail to reach a withdrawal agreement.

Some pharmaceutical companies including AstraZeneca have warned of medicine shortages in the event of a 'no deal' Brexit.

More than 2,600 drugs have some part of their manufacturing carried out in Britain. Britain exports some 45 million medical packs to EU countries each month, industry figures show, while 37 million flow to Britain from the EU.

France's largest drugmaker Sanofi said in August it would increase medicine stockpiles in Britain, echoing moves made by GlaxoSmithKline, Roche and Novartis.

"In business, uncertainty often forces you to make decisions. But what is frustrating is to have to do so when the existing system works very well," Johansson said. "This is costing us money and brings us no benefit."

($1 = 0.7602 pounds)

(Reporting by Inti Landauro; Editing by Richard Lough and Mark Potter)

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -1.40% 7766 Delayed Quote.2.09%
CHANGE INC. -2.31% 8050 End-of-day quote.453.65%
GLAXOSMITHKLINE PLC -0.95% 1291.8 Delayed Quote.-27.39%
NOVARTIS AG 0.53% 71.49 Delayed Quote.-22.21%
ROCHE HOLDING AG 0.29% 294.75 Delayed Quote.-6.13%
SANOFI -1.10% 77.37 Real-time Quote.-13.67%
share with twitter share with LinkedIn share with facebook
All news about ASTRAZENECA PLC
10/30SINOVAC BIOTECH : Brazil will buy China COVID-19 vaccine, VP Mourão says, contra..
10/30THE LATEST : U.S. COVID-19 cases surge past 9 million
10/30Lonza to make COVID-19 antibody combination for AstraZeneca
10/30Pfizer, Astra Vaccine With Oxford Under Accelerated UK Reviews- Bloomberg Ne..
10/30ASTRAZENECA : sells commercial rights to two drugs in $400 million deal
10/30ASTRAZENECA : Atacand to be divested to Cheplapharm in more than 70 countries
10/30ASTRAZENECA : to Sell Atacand Rights in Around 70 Countries for $400 Million
10/30BioNTech CEO expects data from late-stage study soon
10/30LONZA : to make COVID-19 antibody combination for AstraZeneca
10/29EU to fund transfer of COVID-19 patients across borders to prevent hospitals ..
More news
Financials (USD)
Sales 2020 26 659 M - -
Net income 2020 3 027 M - -
Net Debt 2020 13 202 M - -
P/E ratio 2020 46,6x
Yield 2020 2,80%
Capitalization 132 B 132 B -
EV / Sales 2020 5,45x
EV / Sales 2021 4,75x
Nbr of Employees 70 600
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 118,34 $
Last Close Price 100,57 $
Spread / Highest target 54,6%
Spread / Average Target 17,7%
Spread / Lowest Target -34,4%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-6.01%361 159
ROCHE HOLDING AG-6.13%275 049
PFIZER INC.-9.44%196 047
MERCK & CO., INC.-17.31%191 944
NOVARTIS AG-22.21%177 493